South Korean toxin maker stages international training summit in Jeju, signaling aggressive push into Western markets.
Daewoong Pharmaceutical gathered Nabota distribution partners from 22 countries in Jeju for a global training and strategy summit. The event underscores Daewoong's intent to scale Nabota—its botulinum toxin—beyond South Korea and into North America, Europe, and Asia-Pacific.
Nabota is already approved in South Korea, China, and several other markets. Daewoong has been filing for U.S. FDA approval and expanding manufacturing capacity. A 22-country partner convening signals distribution deals are being finalized and sales teams are being trained on positioning, dosing protocols, and rebate structures.
Daewoong stages Nabota training summit across 22 countries
For U.S. practices, Nabota represents a third major toxin option if approved—after Botox (Allergan/AbbVie) and Dysport (Galderma). Daewoong's playbook mirrors Evolus with Jeuveau: aggressive international rollout, competitive unit pricing, and direct-to-practice relationships. Watch for FDA decision timing and launch pricing.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
